Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 20;16(9):2591–2604. doi: 10.1158/1078-0432.CCR-09-2443

Figure 3.

Figure 3

Doxorubicin and TRAIL combination decreases fibrosarcoma (HT1080) growth in vivo. A) Tumor growth curves per treatment group (left; n=10mice/group, p<0.01) and tumor pictures (right upper panel). Box plots (right lower panel) depict average tumor weights at termination of the study (p<0.001); B) Ki-67 immunoflorescence (blue =nuclei, green = Ki-67) and TUNEL staining (blue = nuclei, green =TUNEL) of HT1080 xenograft specimens (selected for presence of viable tumor shown in H+E); C) DR4 (green) and DR5 (red) immunoflorescent staining of HT1080 xenografts (nuclei are depicted in blue).